TPF experimental

Small molecule

SShanghai Jiao Tong University School of Medicine

TPF experimental is one of 29 small molecule programs targeting Oral Squamous Cell Carcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral Squamous Cell CarcinomaActive, not recruiting

Oral Squamous Cell CarcinomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Oral Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

—2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Aldara

BBausch Health Americas, Inc.

One-Alpha

1 5

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 6

Beyfortus

BeiGene

Phase 2

1 7

Opdivo

Bristol-Myers Squibb

Phase 2

—8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

2 10

Tuoyi

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Induction Chemotherapy2 trials

GDF15 Based TPF Induction Chemotherapy for OSCC Patients

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02285530·72 enrolled

A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02285543·10 enrolled

Treatment1 trial

InductionChemo-Radio-Antibody-Treatment

Completed·—·Phase 2·NCT01181401·94 enrolled

Oral Squamous Cell Carcinoma1 trial

TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT01542931·256 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TPF experimental. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TPF experimental compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TPF experimental. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SShanghai Jiao Tong University School of Medicine

TPF experimental

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Induction Chemotherapy2 trials

Treatment1 trial

Oral Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News